GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)– Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, today announced the appointment of Anu Hoey as Chief Business Officer, responsible for leading business and corporate development. “We are thrilled to welcome Anu to our team to help drive our…
Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancers and infectious disease.
Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that will alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. ImmunoPhage™️ is more than a therapeutic platform: it is a treatment paradigm that has received positive FDA feedback. Its most advanced program, SNS-301, is currently enrolling patients in Phase 2 clinical trials.
Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.